Abstract
Simple SummaryDespite immune checkpoint inhibitors’ (ICIs) improved overall survival in urothelial carcinoma patients, only a minority of them benefit from immunotherapy. Therefore, there is an unmet clinical need to identify biomarkers which are useful to select the patients who are most likely to respond to ICIs. This review describes the prognostic and predictive role, and potential clinical applicability, of patient- and tumour-related factors. These factors include new molecular classes, tumour mutational burden, mutational signatures, circulating tumour DNA, programmed death-ligand 1, inflammatory indices and clinical characteristics. This summary may help clinicians to assess patients who are considered for ICI treatment, and may drive further prospective research on these biomarkers.In recent years, the treatment landscape of urothelial carcinoma has significantly changed due to the introduction of immune checkpoint inhibitors (ICIs), which are the standard of care for second-line treatment and first-line platinum-ineligible patients with advanced disease. Despite the overall survival improvement, only a minority of patients benefit from this immunotherapy. Therefore, there is an unmet need to identify prognostic and predictive biomarkers or models to select patients who will benefit from ICIs, especially in view of novel therapeutic agents. This review describes the prognostic and predictive role, and clinical readiness, of clinical and tumour factors, including new molecular classes, tumour mutational burden, mutational signatures, circulating tumour DNA, programmed death-ligand 1, inflammatory indices and clinical characteristics for patients with urothelial cancer treated with ICIs. A classification of these factors according to the levels of evidence and grades of recommendation currently indicates both a prognostic and predictive value for ctDNA and a prognostic relevance only for concomitant medications and patients’ characteristics.
Highlights
Worldwide, urothelial carcinoma (UC) represents the seventh most common cancer and the ninth most deadly tumour, with about 212,000 related deaths [1].For a long time, the only effective treatment of metastatic UC was platinumbased chemotherapy, which is still the standard of care in the first-line setting [2]
Three retrospective analyses investigated radiomics from baseline contrast-enhanced with chemotherapy yet; further studies on larger with populations chemotherapy and yet; external further validation studies on are larger pop and survival outcomes in for patients with have and and survival melanoma outcomes receiving in patients and none of these radiomics-based models have been a Conclusions none of these radiomics-based models been assessed in patients with
Three retrospective from baseline analyses contrast-enhanced investigated radiomic with chemotherapy yet; further studies on larger with populations chemotherapy and yet; external further validation studies on are larger pop lyses investigated radiomics from baseline contrast-enhanced
Summary
Sara Elena Rebuzzi 1,2, *,† , Giuseppe Luigi Banna 3,† , Veronica Murianni 4 , Alessandra Damassi 5 , Emilio Francesco Giunta 6 , Filippo Fraggetta 7 , Ugo De Giorgi 8 , Richard Cathomas 9 , Pasquale Rescigno , Matteo Brunelli and Giuseppe Fornarini 4. There is an unmet clinical need to identify biomarkers which are useful to select the patients who are most likely to respond to ICIs. This review describes the prognostic and predictive role, and potential clinical applicability, of patient- and tumour-related factors. This review describes the prognostic and predictive role, and potential clinical applicability, of patient- and tumour-related factors These factors include new molecular classes, tumour mutational burden, mutational signatures, circulating tumour DNA, programmed death-ligand 1, inflammatory indices and clinical characteristics. This summary may help clinicians to assess patients who are considered for ICI treatment, and may drive further prospective research on these biomarkers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
